FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2507575345> ?p ?o ?g. }

• W2507575345 abstract "Abstract Introduction: Peripheral T-cell lymphomas (PTCL) are heterogeneous diseases, lightly sensitive to chemotherapy, with an adverse outcome and a 5-year survival rate of about 30%. Allogeneic hematopoietic stem cell transplant (allo-SCT) can lead to durable remission even for patients (pts) who show poor response to chemotherapy. Several observations argue for a Graft Versus Lymphoma (GVL) effect in PTCL. However, allo-SCT is not consensually recommended, at least in first line therapy. The aim of the current study is to highlight GVL effect in PTCL. To do so, we evaluated the benefits of immune modulation on disease control (donor lymphocyte infusions (DLI) and immunosuppressive therapy tapering) with analysis of outcome in pts who relapsed after allo-SCT. Patient selection and methods: Between 1988 and 2012, 373 pts received an allo-SCT for treatment of PTCL. 80 pts in relapse after allo-SCT were identified in 27 SFGM-TC(French Society of Bone Marrow Transplantation and Cell Therapies) transplant centers. Exhaustive data were collected for 63 pts. Median age at transplant was 45 years; 67% were male. The main histopathologic subtypes were T-nos (20, 32%), primary cutaneous TCL (13, 21%) and anaplastic large TCL (11, 17%). Others were angioimmunoblastic TCL (8), T/NK lymphomas (5), HTLV1 lymphomas (5) and EIATL (1). At transplant, 38% were in complete remission (CR), 43% in partial remission (PR) and 19% had progressive disease. Median number of previous lines of treatment was 2 and 25% of the pts had previously received an autologous SCT. Conditioning regimen was myeloablative for 23 pts and non-myeloablative for 40. At relapse, pts were treated with either non-immunologic-based strategy (chemotherapy, radiotherapy) or immune modulation (DLI and/or discontinuation of immunosuppressive therapy), or both (Figure 1). We analyzed their outcomes according to the treatment they received at relapse. Results: Relapse occurred at a median time of 204 days after transplant (interquartile range: 49-190 days); seventeen pts had a localized cutaneous relapse (7 Mycosis fungoides, 2 angioimmunoblastic TCL, 3 T-nos, 3 anaplastic TCL and 2 NK/TCL). Among the 14 pts (22%) who received DLI (DLI alone: 5, DLI + radiation and/or chemotherapy: 9), 9 obtained a response (7CR, 2 PR) and 2 had a stable disease (SD) status (overall response rate: 78%). Six of these 14 pts remained alive at last follow up. Median overall survival (OS) of these 14 pts was 23.6 months. Among the 49 pts who did not receive DLI, immunosuppressive therapy was tapered or stopped for 23. Sustained CR after tapering immunosuppressive drugs was observed in2 pts along with extensive chronic graft versus host disease (cGVHD). In the non-DLI group, 30 out of 49 pts received a radio/chemotherapy treatment with a response rate of 50% and a 1-year survival rate of 25% after relapse. Among the 13/49 pts who experienced a response in this group, six developed a cGVHD after relapse. Median OS of these 49 pts was 3.6 months. Median follow up was 40 months for the whole population. Conclusion: DLI alone or in association with other therapies, when possible, seems to be an efficient salvage option. This study suggests the benefit of DLI in cases of post transplant relapse for PTCL and supports the existence of a GVL effect in these diseases. These findings could potentially lead to the set up of a proactive immune modulation strategy after transplant for pts with high-risk disease. However, the short time frame from transplant to relapse currently observed, might limit the feasibility of this therapeutic option. Figure 1: Combination treatments at relapse and response: Figure 1:. Combination treatments at relapse and response: Figure 2: Overall survival in non- DLI group (n=49) Figure 2:. Overall survival in non- DLI group (n=49) Figure 3: Overall survival in DLI group (n=14): Figure 3:. Overall survival in DLI group (n=14): Disclosures No relevant conflicts of interest to declare." @default.
• W2507575345 created "2016-09-16" @default.
• W2507575345 creator A5008084507 @default.
• W2507575345 creator A5011668592 @default.
• W2507575345 creator A5011865826 @default.
• W2507575345 creator A5019451763 @default.
• W2507575345 creator A5021867441 @default.
• W2507575345 creator A5025108931 @default.
• W2507575345 creator A5025925500 @default.
• W2507575345 creator A5033775906 @default.
• W2507575345 creator A5036207495 @default.
• W2507575345 creator A5037324033 @default.
• W2507575345 creator A5037455697 @default.
• W2507575345 creator A5044449649 @default.
• W2507575345 creator A5045374333 @default.
• W2507575345 creator A5046436694 @default.
• W2507575345 creator A5050597176 @default.
• W2507575345 creator A5050692336 @default.
• W2507575345 creator A5050987906 @default.
• W2507575345 creator A5057098654 @default.
• W2507575345 creator A5066352955 @default.
• W2507575345 creator A5072757261 @default.
• W2507575345 creator A5074161015 @default.
• W2507575345 creator A5076452184 @default.
• W2507575345 creator A5076453784 @default.
• W2507575345 creator A5079934679 @default.
• W2507575345 date "2014-12-06" @default.
• W2507575345 modified "2023-10-18" @default.
• W2507575345 title "Effect of Immune Modulation for Peripheral T-Cell Lymphoma in Response to Relapse after Allogeneic Hematopoietic Stem Cell Transplant: A Study of 63 Patients By the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)." @default.
• W2507575345 doi "https://doi.org/10.1182/blood.v124.21.3963.3963" @default.
• W2507575345 hasPublicationYear "2014" @default.
• W2507575345 type Work @default.
• W2507575345 sameAs 2507575345 @default.
• W2507575345 citedByCount "0" @default.
• W2507575345 crossrefType "journal-article" @default.
• W2507575345 hasAuthorship W2507575345A5008084507 @default.
• W2507575345 hasAuthorship W2507575345A5011668592 @default.
• W2507575345 hasAuthorship W2507575345A5011865826 @default.
• W2507575345 hasAuthorship W2507575345A5019451763 @default.
• W2507575345 hasAuthorship W2507575345A5021867441 @default.
• W2507575345 hasAuthorship W2507575345A5025108931 @default.
• W2507575345 hasAuthorship W2507575345A5025925500 @default.
• W2507575345 hasAuthorship W2507575345A5033775906 @default.
• W2507575345 hasAuthorship W2507575345A5036207495 @default.
• W2507575345 hasAuthorship W2507575345A5037324033 @default.
• W2507575345 hasAuthorship W2507575345A5037455697 @default.
• W2507575345 hasAuthorship W2507575345A5044449649 @default.
• W2507575345 hasAuthorship W2507575345A5045374333 @default.
• W2507575345 hasAuthorship W2507575345A5046436694 @default.
• W2507575345 hasAuthorship W2507575345A5050597176 @default.
• W2507575345 hasAuthorship W2507575345A5050692336 @default.
• W2507575345 hasAuthorship W2507575345A5050987906 @default.
• W2507575345 hasAuthorship W2507575345A5057098654 @default.
• W2507575345 hasAuthorship W2507575345A5066352955 @default.
• W2507575345 hasAuthorship W2507575345A5072757261 @default.
• W2507575345 hasAuthorship W2507575345A5074161015 @default.
• W2507575345 hasAuthorship W2507575345A5076452184 @default.
• W2507575345 hasAuthorship W2507575345A5076453784 @default.
• W2507575345 hasAuthorship W2507575345A5079934679 @default.
• W2507575345 hasConcept C126322002 @default.
• W2507575345 hasConcept C143998085 @default.
• W2507575345 hasConcept C203014093 @default.
• W2507575345 hasConcept C2776090121 @default.
• W2507575345 hasConcept C2776694085 @default.
• W2507575345 hasConcept C2777408962 @default.
• W2507575345 hasConcept C2777891184 @default.
• W2507575345 hasConcept C2778336483 @default.
• W2507575345 hasConcept C2779338263 @default.
• W2507575345 hasConcept C2779695342 @default.
• W2507575345 hasConcept C2911091166 @default.
• W2507575345 hasConcept C71924100 @default.
• W2507575345 hasConcept C8891405 @default.
• W2507575345 hasConcept C90924648 @default.
• W2507575345 hasConceptScore W2507575345C126322002 @default.
• W2507575345 hasConceptScore W2507575345C143998085 @default.
• W2507575345 hasConceptScore W2507575345C203014093 @default.
• W2507575345 hasConceptScore W2507575345C2776090121 @default.
• W2507575345 hasConceptScore W2507575345C2776694085 @default.
• W2507575345 hasConceptScore W2507575345C2777408962 @default.
• W2507575345 hasConceptScore W2507575345C2777891184 @default.
• W2507575345 hasConceptScore W2507575345C2778336483 @default.
• W2507575345 hasConceptScore W2507575345C2779338263 @default.
• W2507575345 hasConceptScore W2507575345C2779695342 @default.
• W2507575345 hasConceptScore W2507575345C2911091166 @default.
• W2507575345 hasConceptScore W2507575345C71924100 @default.
• W2507575345 hasConceptScore W2507575345C8891405 @default.
• W2507575345 hasConceptScore W2507575345C90924648 @default.
• W2507575345 hasLocation W25075753451 @default.
• W2507575345 hasOpenAccess W2507575345 @default.
• W2507575345 hasPrimaryLocation W25075753451 @default.
• W2507575345 hasRelatedWork W1016550661 @default.
• W2507575345 hasRelatedWork W2180809703 @default.
• W2507575345 hasRelatedWork W2341077074 @default.
• W2507575345 hasRelatedWork W2497772578 @default.
• W2507575345 hasRelatedWork W2549756908 @default.
• W2507575345 hasRelatedWork W2557048661 @default.
• W2507575345 hasRelatedWork W2573444275 @default.
• W2507575345 hasRelatedWork W2580025711 @default.
• W2507575345 hasRelatedWork W2581512527 @default.
• W2507575345 hasRelatedWork W2590573988 @default.

• next